News Center

With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.

28

2024

-

11

Co-create a new blueprint for growth! Keyuan Pharmaceutical & Linuo Pharmaceutical showcased at the 18th Growth-Oriented Pharmaceutical Enterprises Development Conference!

Classification:

News

行业新闻

Corporate News


 

       Recently, the highly anticipated 18th Growth-Oriented Pharmaceutical Enterprises Development Conference was grandly held at the Baixiang Convention Center in Xiamen."Growth Power - Common Challenges and Responsibilities"was the theme, gathering many leading companies, experts, scholars, and investment institutions in the domestic pharmaceutical industry to explore the future development path of the pharmaceutical industry based on responsibility and driven by challenges.

 

       Keyuan Pharmaceutical (stock code: 301281.SZ) and Linuo Pharmaceutical made their appearance at this conference and won multiple awards.

       On the path of exploring the growth power of pharmaceutical companies, "common challenges and responsibilities" have become keywords that cannot be ignored.In the face of a rapidly changing market environment, increasingly stringent regulatory requirements, and ever-upgrading consumer demands,pharmaceutical companies need to work hand in hand.

 

       Together, they must address challenges in product quality, technological innovation, and social responsibility.In facing the challenges and responsibilities of growth, Keyuan Pharmaceutical and Linuo Pharmaceutical have demonstrated exceptional efforts and commitment.The company focuses on technological research and development, intelligent manufacturing, and cultural marketing as its main driving forces,investing substantial resources to promote product upgrades, establishing provincial-level enterprise technology centers, and Jinan municipal-level postdoctoral innovation practice bases, and has formed long-term stable cooperative relationships with several research institutions and universities,jointly carrying out scientific research projects, technology transfer, and talent cultivation,

 

       achieving steady development of the enterprise.The company actively builds high-end intelligent manufacturing factories that integrate the latest technology with digital and information technology,forming a safe, green, low-carbon, and environmentally friendly smart industrial park,

 

 

       making positive contributions to sustainable development and practicing corporate social responsibility through concrete actions.At the conference, Keyuan Pharmaceutical and Linuo Pharmaceutical engaged in in-depth exchanges with attendees and actively participated in various thematic activities, including"Capital Empowering Industrial Reconstruction and Renewal" and "Grassroots Medical Development Conference,"

       analyzing the development trends of the pharmaceutical industry and sharing successful experiences.Mr. Jiang Hongsheng, Chairman and President of Keyuan Pharmaceutical, served as the host of this capital sub-forum,leading the attendees to explore new models of capital and industry integration, providing valuable ideas and suggestions for the transformation and upgrading of pharmaceutical health enterprises.

       At this conference, Keyuan Pharmaceutical and Linuo Pharmaceutical received multiple honors.Due to their outstanding performance in brand building, market expansion, and quality assurance,Linuo Pharmaceutical won the "Annual Excellence Brand Award."For his outstanding contributions and influence in the industry,

 

       Mr. Jiang Hongsheng was awarded the "Annual Influential Entrepreneur" honor at the conference.Honor is not only a high recognition of strength but also an effective motivation for future development.Keyuan Pharmaceutical and Linuo Pharmaceutical will face the challenges and opportunities of growth witha more open mindset, innovative thinking, and pragmatic actions,actively enhancing the core competitiveness of the industry in collaboration with upstream and downstream partners in the industrial chain, continuously stimulating the innovative vitality and endogenous power of the pharmaceutical health industry,